Statins were linked to a 15% lower risk of developing glaucoma, but the study does not prove they caused the difference. Researchers compared more than 210,000 people taking Statins with 210,000 similar people without recorded use. Everyone had a recorded follow-up eye visit. The study focused on open-angle glaucoma, a disease that damages the eye’s nerve. At five years, 4,771 people taking the medicines had developed glaucoma. That was 2.3%, compared with 5,491 people, or 2.6%, in the comparison group. The actual gap was 0.3 percentage points. That gives useful context to the reported 15% lower risk. A separate comparison looked at people who already had glaucoma. It included over 30,000 taking the medicines and almost 250,000 not taking them. At five years, use was linked to 36% lower risk of surgery involving an incision. The risk of keyhole surgery to lower eye pressure was 55% lower. Laser treatment risk was 60% lower, and use of pressure-lowering eye drops was 12% lower. Links to lower treatment risk remained at 10 years. The researchers suggested that reduced inflammation and possible nerve protection might help explain the findings. Those ideas still need testing. A link is not proof of protection. This comparison cannot show that the medicines themselves prevented glaucoma. For BioSocial members tracking LDL Cholesterol, this adds an eye-health question to the conversation. Keeping eye-exam results alongside bloodwork and medication history could make community comparisons more useful. Your own timeline can add context, without proving what caused a change. What have your eye-exam results shown over time alongside your cholesterol numbers and medication history?